Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

NEW YORK, September 29, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that from September 14, 2026 to September 28, 2026, the Compensation Committee of Immunic's Board of Directors granted inducement equity grants covering an aggregate of 196,350 shares of common stock of the company under the Immunic, Inc. 2026 Inducement Equity Compensation Plan (the "Options") to seven new employees. The Options were granted as an inducement material to the commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). The Options will be time vested, with 25% vesting on the first anniversary of the applicable date of hire of each individual and the remainder vesting on a monthly basis in 36 equal installments, subject to each such employee's continued employment on each vesting date.